Abacus Bioscience
Latest round
- Seed
Last raised
- Jan 2023
Total raised
- $4.4M
Investors
- 4
About Abacus Bioscience
Based in Washington, US, and founded in 2017, Abacus Bioscience provides novel immunotherapeutic treatments for managing cancer and antiviral diseases. As of 2023, the company is headed by its CEO Alan Wahl who co-founded the firm. The company provides cutting-edge immunotherapeutic therapies with a CD180 backbone for treating viral and cancerous disorders. It offers medical professionals a comprehensive platform that they can use to plug and play with different cancer or viral antigens.
Who invested in Abacus Bioscience
4 investors across 1 round
See all investors in Abacus Bioscience
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Jan 19, 2023
Amount
$4.4M
Investors
Questions about Abacus Bioscience
Who invested in Abacus Bioscience?
Abacus Bioscience has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Abacus Bioscience raised?
Abacus Bioscience has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Abacus Bioscience last raise money?
Abacus Bioscience's most recent round on record is a Seed, in Jan 2023.
What does Abacus Bioscience do?
Based in Washington, US, and founded in 2017, Abacus Bioscience provides novel immunotherapeutic treatments for managing cancer and antiviral diseases.
Where is Abacus Bioscience headquartered?
Abacus Bioscience is headquartered in Seattle, US.
Which VCs invest in companies like Abacus Bioscience?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Abacus Bioscience's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Abacus Bioscience? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.